Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

AstraZeneca Pharma India wins CDSCO approval for Enhertu (trastuzumab deruxtecan) in HER2-positive early breast cancer neoadjuvant setting
Antibody-drug conjugate, cancer, breast cancer, HER2-positive, neoadjuvant treatment, trastuzumab deruxtecan - Read more

AbbVie's Rinvoq (upadacitinib) earns dual EU approvals for non-segmental vitiligo and severe alopecia areata via Ph3 data
Small molecule, autoimmune, JAK inhibitor, vitiligo, alopecia areata, upadacitinib - Read more

Kyverna Therapeutics, ElevateBio strike five-year clinical and commercial supply deal for autoimmune CAR-T therapy
Manufacturing agreement, autoimmune, cell therapy, rare disease, commercialization- Read more

Vertex Pharmaceuticals, AbCellera collaborate on autoimmune TCE discovery with $28M upfront
Research collaboration, autoimmune, antibody, drug discovery, milestone payments - Read more

Evinova, Merck KGaA launch multi-year strategic collaboration to accelerate AI-native clinical development
Strategic collaboration, AI/ML, clinical trials, R&D, drug discovery - Read more

Daré Bioscience collaborates with MyMenopauseRx to expand telehealth access for DARE to PLAY sildenafil cream
Strategic collaboration, women's health, telehealth, commercialization, small molecule - Read more

CORE Biomedicine licenses exclusive global preclinical oncology programs from Eisai
Licensing deal, oncology, small molecule, drug discovery, precision medicine - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

ProMIS Neurosciences reports positive Ph1b interim safety and biomarker data for PMN310 (amyloid-beta oligomer) in Alzheimer's disease
Antibody, neurological, monoclonal antibody, Alzheimer's disease, amyloid-beta oligomers, APOE4 - Read more

Acrosian launches as AI-focused biometrics CRO targeting emerging biotechs and global pharma companies
AI-driven CRO, biopharma services, operational, strategic - Read more

Incyte raises Opzelura 2026 sales guidance above $1B following CMS Medicaid rebate settlement
Small molecule, dermatology, revenue impact, regulatory - Read more

Teva's branded drug surge, led by Ajovy's near-$1B milestone, offsets generics revenue decline
Small molecule, neurological, financial, revenue impact - Read more

Biogen flips 2026 revenue guidance to growth after Apellis Pharmaceuticals acquisition and strong new drug sales
Small molecule, neurological, financial, revenue impact - Read more

Basilea Pharmaceutica receives $30M BARDA funding, advancing Phase 3 antifungal fosmanogepix
Infectious disease, antifungal, small molecule, clinical-stage - Read more

CORE Biomedicine raises $21M Series A, advancing lineage-based precision oncology therapeutics
Oncology, precision medicine, lineage-based therapeutics, preclinical - Read more

Enlivex raises $400M private placement, advancing prediction markets treasury and Allocetra immunotherapy
Clinical-stage, immunotherapy, osteoarthritis, prediction markets treasury - Read more

Johnson & Johnson proposes $5.5B settlement to resolve 76,000 talc ovarian cancer lawsuits
Talc/consumer product, ovarian cancer, major transaction, financial - Read more

Eli Lilly tops Norstella's inaugural biopharma productivity index, rising from 16th to first in five years
GLP-1, metabolic disease, competitive, strategic - Read more

CG Life acquires AI-native agency The Considered+AI to modernize rare disease pharma marketing
Rare disease, AI, strategic, major transaction - Read more

Caldera Therapeutics reverse merges with Synlogic, secures $278M financing to advance IBD bispecific antibody
Bispecific antibody, autoimmune, major transaction, financial - Read more

Processa Pharmaceuticals acquires Vidya Therapeutics for BTK inhibitor VT-7208, rivaling Novartis' Rhapsido
Small molecule, autoimmune, major transaction, investment - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Novo Nordisk ordered to face shareholder fraud claims over CagriSema dosing protocol concealment
Small molecule, obesity, shareholder fraud, financial - Read more

PMCPA sanctions AGB Pharma for misleadingly omitting fertility warnings in Adaflex melatonin promotional materials
Small molecule, sleep disorders, regulatory, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here